Penumbra, Inc.
PEN
Clasificación en acciones
#1679
Penumbra, Inc., together with its subsidiaries, designs, develops,... Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Precio por acción
$323.80
Capitalización bursátil
$12.75B
Cambio (1 día)
0.32%
Cambio (1 año)
30.76%
País
US
Comercio Penumbra, Inc. (PEN)
Categoría
Healthcare
Ratio P/E de Penumbra, Inc. (PEN)
Ratio P/E al October 2026 TTM: 78.27
Según los últimos informes financieros y el precio de las acciones de Penumbra, Inc., el P/E actual (TTM) de la empresa es 78.27. Al final de 2023, la empresa tenía un P/E de 106.20.
Historial del ratio P/E de Penumbra, Inc. desde 2012 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2026 (TTM) | 78.27 | -88.05% |
| 2024 | 654.78 | 516.55% |
| 2023 | 106.20 | -102.53% |
| 2022 | -4.20K | -310.34% |
| 2021 | 2.00K | -601.49% |
| 2020 | -398.62 | -438.38% |
| 2019 | 117.80 | -82.37% |
| 2018 | 668.05 | 0.25% |
| 2017 | 666.36 | 407.88% |
| 2016 | 131.20 | -51.92% |
| 2015 | 272.88 | -39.48% |
| 2014 | 450.91 | 82.58% |
| 2013 | 246.96 | -52.23% |
| 2012 | 517.00 | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| 33.11 | -57.70% |
US
|
|
| 21.39 | -72.67% |
IE
|
|
| 28.94 | -63.02% |
US
|
|
| 17.34 | -77.85% |
US
|
|
| - | - |
DE
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.